Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9390)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Dec 15, 2018 (publication date) through Dec 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Oncology
ISSN
1948-5204
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chung MJ, Kang H, Kim HG, Hyun JJ, Lee JK, Lee KH, Noh MH, Kang DH, Lee SH, Bang S, Pancreatobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer. Multicenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer. World J Gastrointest Oncol 2018; 10(12): 505-515 [PMID: 30595804 DOI: 10.4251/wjgo.v10.i12.505] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5204/full/v10/i12/505.htm |
| Number | Citing Articles |
| 1 |
Haruo Miwa, Kazuya Sugimori, Tomohiro Ishii, Akihiro Funaoka, Hiromi Tsuchiya, Yoshimasa Suzuki, Makoto Sugimori, Masaki Nishimura, Yuichiro Tozuka, Satoshi Komiyama, Takeshi Sato, Takashi Kaneko, Kazushi Numata, Shin Maeda. Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas. Internal Medicine 2021; 60(16): 2607 doi: 10.2169/internalmedicine.6755-20
|
| 2 |
Hangyu Zhang, Zhou Tong, Lulu Liu, Qihan Fu, Xudong Zhu, Xiaomeng Dai, Xuanwen Bao, Weijia Fang, Yi Zheng, Peng Zhao. Oxaliplatin plus irinotecan vs irinotecan as second-line treatment in pancreatic cancer patients: a randomized–controlled open-label Phase II study. Gastroenterology Report 2022; 11 doi: 10.1093/gastro/goac088
|
| 3 |
Y. E. Chikhareva, M. Yu. Fedyanin, I. S. Bazin, I. A. Pokataev, A. A. Tryakin. Systemic therapy for metastatic pancreatic cancer. Malignant tumours 2023; 13(4): 60 doi: 10.18027/2224-5057-2023-13-4-60-68
|
| 4 |
Takafumi Mie, Takashi Sasaki, Takeshi Okamoto, Tsuyoshi Takeda, Chinatsu Mori, Takaaki Furukawa, Akiyoshi Kasuga, Masato Matsuyama, Masato Ozaka, Naoki Sasahira. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Japanese Journal of Clinical Oncology 2022; 52(12): 1399 doi: 10.1093/jjco/hyac145
|
| 5 |
Farshid Dayyani, Teresa Macarulla, Andrew Johnson, Zev A. Wainberg. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review. Cancer Treatment Reviews 2023; 113: 102502 doi: 10.1016/j.ctrv.2022.102502
|
| 6 |
Yasuko Murakawa, Kazunori Ootsuka, Makoto Abue. The Appropriate First-Line Chemotherapy Regimen for Incurable Pancreatic Cancer in Clinical Practice: A Consideration of Patients' Overall Survival and Quality of Life. Journal of Pancreatic Cancer 2021; 7(1): 48 doi: 10.1089/pancan.2021.0005
|
| 7 |
Shun Tezuka, Makoto Ueno, Satoshi Kobayashi, Tomomi Hamaguchi, Yui Yamachika, Ritsuko Oishi, Shuhei Nagashima, Taito Fukushima, Manabu Morimoto, Maeda Shin. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Pancreatology 2022; 22(6): 789 doi: 10.1016/j.pan.2022.06.004
|
| 8 |
Masashi Sawada, Akiyoshi Kasuga, Takafumi Mie, Takaaki Furukawa, Takanobu Taniguchi, Koshiro Fukuda, Yuto Yamada, Tsuyoshi Takeda, Ryo Kanata, Masato Matsuyama, Takashi Sasaki, Masato Ozaka, Naoki Sasahira. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer 2020; 20(1) doi: 10.1186/s12885-020-06945-8
|
| 9 |
Sara Cherri, Silvia Noventa, Alberto Zaniboni. Pancreatic adenocarcinoma: Beyond first line, where are we?. World Journal of Gastroenterology 2021; 27(17): 1847-1863 doi: 10.3748/wjg.v27.i17.1847
|
| 10 |
Francesca Foschini, Fabiana Napolitano, Alberto Servetto, Roberta Marciano, Eleonora Mozzillo, Anna Chiara Carratù, Antonio Santaniello, Pietro De Placido, Priscilla Cascetta, Giovanni Butturini, Isabella Frigerio, Paolo Regi, Nicola Silvestris, Sabina Delcuratolo, Enrico Vasile, Caterina Vivaldi, Cataldo Bianco, Sabino De Placido, Luigi Formisano, Roberto Bianco. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. Therapeutic Advances in Medical Oncology 2020; 12 doi: 10.1177/1758835920947970
|
| 11 |
Hakon Blomstrand, Atul Batra, Winson Y Cheung, Nils Oskar Elander. Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer. World Journal of Clinical Oncology 2021; 12(9): 787-799 doi: 10.5306/wjco.v12.i9.787
|
| 12 |
H.S. Park, B. Kang, H.J. Chon, H.-S. Im, C.-K. Lee, I. Kim, M.J. Kang, J.E. Hwang, W.K. Bae, J. Cheon, J.O. Park, J.Y. Hong, J.H. Kang, J.H. Kim, S.H. Lim, J.W. Kim, J.-W. Kim, C. Yoo, H.J. Choi. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG). ESMO Open 2021; 6(2): 100049 doi: 10.1016/j.esmoop.2021.100049
|
| 13 |
Christopher Gromisch, Motaz Qadan, Mariana Albuquerque Machado, Kebin Liu, Yolonda Colson, Mark W. Grinstaff. Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease. Cancer Research 2020; 80(16): 3179 doi: 10.1158/0008-5472.CAN-19-2731
|
| 14 |
Shun Tezuka, Makoto Ueno, Ritsuko Oishi, Shuhei Nagashima, Yusuke Sano, Kuniyuki Kawano, Satoshi Tanaka, Taito Fukushima, Hiroyuki Asama, Naoki Konno, Satoshi Kobayashi, Manabu Morimoto, Shin Maeda. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second‐line treatment regimen for unresectable pancreatic cancer: A real‐world analysis. Cancer Medicine 2022; 11(4): 1088 doi: 10.1002/cam4.4512
|
| 15 |
Se-Il Go, Sang-Cheol Lee, Woo Kyun Bae, Dae Young Zang, Hyun Woo Lee, Joung Soon Jang, Jun Ho Ji, Jung Hoon Kim, Sanggon Park, Sun Jin Sym, Yaewon Yang, So Yeon Jeon, In Gyu Hwang, Sung Yong Oh, Jung Hun Kang. Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients: A randomised controlled trial (MPACA-3). European Journal of Cancer 2021; 157: 21 doi: 10.1016/j.ejca.2021.08.002
|
| 16 |
Sara Pusceddu, Michele Ghidini, Martina Torchio, Francesca Corti, Gianluca Tomasello, Monica Niger, Natalie Prinzi, Federico Nichetti, Andrea Coinu, Maria Di Bartolomeo, Mary Cabiddu, Rodolfo Passalacqua, Filippo de Braud, Fausto Petrelli. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancers 2019; 11(4): 484 doi: 10.3390/cancers11040484
|
| 17 |
Louise S. Rasmussen, Claus W. Fristrup, Benny V. Jensen, Per Pfeiffer, Britta Weber, Mette K. Yilmaz, Laurids Ø. Poulsen, Morten Ladekarl, Kell Østerlind, Jim S. Larsen, Halla Skuladottir, Martin Bøgsted, Ursula G. Falkmer. Patterns of Palliative Chemotherapy and Survival in Patients With Pancreatic Cancer Focusing on Age. Pancreas 2021; 50(5): 685 doi: 10.1097/MPA.0000000000001833
|
| 18 |
Vidhi M. Shah, Craig Dorrell, Adel Al-Fatease, Brittany L. Allen-Petersen, Yeonhee Woo, Yuliya Bortnyak, Rohi Gheewala, Brett C. Sheppard, Rosalie C. Sears, Adam WG. Alani. Microfluidics Formulated Liposomes of Hypoxia Activated Prodrug for Treatment of Pancreatic Cancer. Pharmaceutics 2022; 14(4): 713 doi: 10.3390/pharmaceutics14040713
|
| 19 |
Tomoyuki Satake, Chigusa Morizane, Yuta Maruki, Akihiro Ohba, Yoshikuni Nagashio, Shunsuke Kondo, Susumu Hijioka, Hideki Ueno, Takuji Okusaka. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer. International Journal of Clinical Oncology 2022; 27(8): 1331 doi: 10.1007/s10147-022-02186-w
|
| 20 |
George Papaxoinis, Athanasios Athanasiadis, Joseph Sgouros, Anastastios Visvikis, Maria Drizou, Emmanouil Kontopodis, Anna Koumarianou, Suzana Stojanovska, Gerasimos Aravantinos, Ippokratis Korantzis, Alexandros Ioannou, Ioannis Varthalitis, Dimitrios Doufexis, Michail Nikolaou, Georgios Lypas, Iliada Bompolaki, Athina Christopoulou, Michael Liontos, Nikolaos Tsoukalas, Davide Mauri, Nikolaos Xenidis, Panagiotis Katsaounis, Georgios Oikonomopoulos, Ioannis Boukovinas. Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. Journal of Oncology 2020; 2020: 1 doi: 10.1155/2020/5304516
|
| 21 |
Yung-Yeh Su, Nai-Jung Chiang, Tai-Jan Chiu, Chien-Jui Huang, Shao-Jung Hsu, Hsin-Chen Lin, Shih-Hung Yang, Youngsen Yang, Wen-Chi Chou, Yen-Yang Chen, Li-Yuan Bai, Chung-Pin Li, Jen-Shi Chen. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation. Biomedical Journal 2024; 47(3): 100696 doi: 10.1016/j.bj.2023.100696
|
| 22 |
Paige T Shelemey, Carla P Amaro, Danny Ng, Vincent Falck, Vincent C Tam. Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment. BMJ Case Reports 2021; 14(5): e238395 doi: 10.1136/bcr-2020-238395
|
| 23 |
Belén Toledo, Chiara Deiana, Fabio Scianò, Giovanni Brandi, Juan Antonio Marchal, Macarena Perán, Elisa Giovannetti. Treatment resistance in pancreatic and biliary tract cancer: molecular and clinical pharmacology perspectives. Expert Review of Clinical Pharmacology 2024; 17(4): 323 doi: 10.1080/17512433.2024.2319340
|
| 24 |
Abdullah Sakin, Suleyman Sahin, Muhammed Mustafa atci, Cumhur Demir, Nurgul Yasar, Caglayan Geredeli, Sener Cihan. The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Sciences 2019; 5(3): 85 doi: 10.1016/j.jons.2019.08.003
|
| 25 |
F. Franco, J. C. Camara, J. I. Martín-Valadés, A. López-Alfonso, D. Marrupe, D. Gutiérrez-Abad, B. Martínez-Amores, A. León, I. Juez, M. Pérez, A. Royuela, A. Ruiz-Casado. Clinical outcomes of FOLFIRINOX and gemcitabine–nab paclitaxel for metastatic pancreatic cancer in the real world setting. Clinical and Translational Oncology 2021; 23(4): 812 doi: 10.1007/s12094-020-02473-w
|
| 26 |
Kenji Ikezawa, Ryosuke Kiyota, Ryoji Takada, Kazuma Daiku, Shingo Maeda, Toshihiro Imai, Yutaro Abe, Yugo Kai, Takuo Yamai, Nobuyasu Fukutake, Tasuku Nakabori, Reiko Ashida, Hiroyuki Uehara, Takahiro Tabuchi, Kazuhiro Katayama, Kazuyoshi Ohkawa. Efficacy and safety of modified fluorouracil/leucovorin plus irinotecan and oxaliplatin (mFOLFIRINOX) compared with S‐1 as second‐line chemotherapy in metastatic pancreatic cancer. JGH Open 2021; 5(6): 679 doi: 10.1002/jgh3.12555
|